The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public alert concerning counterfeit Ozempic, an anti-diabetic drug. The agency revealed that the falsely labeled Ozempic, a solution for injection, has been circulating in markets, specifically in pre-filled pens found in international markets.
NAFDAC, through an official tweet on its handle, disclosed that despite Ozempic not being registered with the agency, its scarcity in the markets due to high global demand has led to its falsification.
The tweet read, “NAFDAC is informing the public about the circulation of pre-filled pens falsely labeled as the diabetes medicine, Ozempic (semaglutide, 1 mg, solution for injection) which was identified at wholesalers in the European Union and the UK as reported by the European Medicines Agency.
“The reports of falsification came in the wake of an increase in demand for Ozempic, which has led to a global shortage situation. The pens have batch numbers, 2D barcodes, and unique serial numbers from genuine Ozempic packs.”
The tweet added that “Ozempic (semaglutide) is not registered by NAFDAC. Although the product is not in the NAFDAC database, it is likely that it might have been distributed in the country through informal markets.”
NAFDAC advised Nigerians to consistently buy medical products only from authorized and licensed suppliers, emphasizing the importance of verifying the authenticity of these products.
“NAFDAC implores importers, distributors, retailers and healthcare providers and patients to always exercise caution and vigilance within the supply chain to avoid the importation, distribution, sale and administration or use of falsified or substandard medicinal products,” the tweet stated.
Note : To submit Press Releases, Statements, and Advert Inquiries for publication on Waffi blog (website) or Television 📺, please use the following contact details: You can send an email to email@example.com or reach us via Whatsapp at 07068286500